Nintedanib (marketed as OFEV by Boehringer Ingelheim) has shown very good results in clinical trials in patients with idiopathic pulmonary fibrosis (IPF). Nevertheless, some patients still experience disease exacerbation when treated with the drug. A case study described the successful reinstallation of the drug after an exacerbation — raising hopes that disease worsening does not necessarily lead to treatment discontinuation.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?